» Articles » PMID: 27574554

Immunohistochemical Analysis of the Wnt/β-catenin Signaling Pathway in Pancreatic Neuroendocrine Neoplasms

Overview
Date 2016 Aug 31
PMID 27574554
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To investigate the role of the Wnt/β-catenin pathway in pancreatic neuroendocrine neoplasms (PanNENs).

Methods: Tissue microarrays containing 88 PanNENs were immunohistochemically labeled with antibodies to β-catenin, E-cadherin, adenomatous polyposis coli (APC), chromogranin and synaptophysin. One case had only metastatic tumors resected, whereas others (n = 87) received pancreatectomy with or without partial hepatectomy. Pathology slides, demographic, clinicopathologic, and follow up data were reviewed. Patients' demographics, clinicopathologic features, and immunohistochemical results from 87 primary tumors were compared between patients with low stage (stage I/II) and high stage (stage III/IV) tumors. In addition, correlation of immunohistochemical results from primary tumors with disease-specific survival (DSS) was evaluated.

Results: Strong membranous β-catenin staining in the primary tumor was observed in all 13 stage III/IV PanNENs as compared to 47% (35/74) of stage I/II tumors (P < 0.01). However, the strong membranous β-catenin staining was unassociated with tumor grade or DSS. Decreased membranous β-catenin staining was associated with decreased membranous E-cadherin labeling. Nuclear β-catenin staining was seen in 15% (2/13) of stage III/IV PanNENs as compared to 0% (0/74) of stage I/II tumors (P = 0.02). The case with metastasectomy only also showed nuclear β-catenin staining. Two of the three cases with nuclear β-catenin staining were familial adenomatous polyposis (FAP) patients. Lack of APC expression was seen in 70% (57/81) of the cases, including the 3 cases with nuclear β-catenin staining. Expression of E-cadherin and APC in primary tumor was not correlated with tumor grade, tumor stage, or disease specific survival.

Conclusion: The Wnt/β-catenin pathway was altered in some PanNENs, but did not Impact DSS. PanNENs in FAP patients demonstrated nuclear β-catenin accumulation and loss of APC.

Citing Articles

Role of endoscopic ultrasound-guided fine needle aspiration biopsies in diagnosing pancreatic neoplasms in the paediatric population: experience from a tertiary center and review of the literature.

Radulovic M, Brecelj J, Gruden A, Flezar M Radiol Oncol. 2024; 58(1):78-86.

PMID: 38378032 PMC: 10878772. DOI: 10.2478/raon-2024-0008.


Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.

Saleh Z, Moccia M, Ladd Z, Joneja U, Li Y, Spitz F Int J Mol Sci. 2024; 25(2).

PMID: 38279330 PMC: 10816436. DOI: 10.3390/ijms25021331.


Pseudoendocrine sarcoma: clinicopathologic, molecular, and epigenetic features of one case.

Vizcaino M, Folpe A, Huffman H, Panchal R, Nielsen G, Kipp B Virchows Arch. 2023; 483(6):899-904.

PMID: 37953374 DOI: 10.1007/s00428-023-03695-3.


FAM83A promotes the progression and metastasis of human pancreatic neuroendocrine tumors by inducing the epithelial-mesenchymal transition via the PI3K/AKT and ERK pathways.

Zhou B, Zhou X, Zhan C, Jin M, Yan S J Endocrinol Invest. 2022; 46(6):1115-1130.

PMID: 36344884 DOI: 10.1007/s40618-022-01959-4.


Gender differences in pancreatic neuroendocrine neoplasms: A retrospective study based on the population of Hubei Province, China.

Fu M, Yu L, Yang L, Chen Y, Chen X, Hu Q Front Endocrinol (Lausanne). 2022; 13:885895.

PMID: 36004340 PMC: 9393376. DOI: 10.3389/fendo.2022.885895.


References
1.
Aoki K, Taketo M . Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci. 2007; 120(Pt 19):3327-35. DOI: 10.1242/jcs.03485. View

2.
Klimstra D . Nonductal neoplasms of the pancreas. Mod Pathol. 2007; 20 Suppl 1:S94-112. DOI: 10.1038/modpathol.3800686. View

3.
Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T . Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res. 2001; 61(18):6656-9. View

4.
Basturk O, Yang Z, Tang L, Hruban R, Adsay V, McCall C . The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015; 39(5):683-90. PMC: 4398606. DOI: 10.1097/PAS.0000000000000408. View

5.
Jiang X, Cao Y, Li F, Su Y, Li Y, Peng Y . Targeting β-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours. Nat Commun. 2014; 5:5809. PMC: 4284642. DOI: 10.1038/ncomms6809. View